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Hye Ju Yeo1, Doosoo Jeon1, Yun Seong Kim1, Woo Hyun Cho1 and Dohyung Kim2*In acute respiratory distress syndrome (ARDS) with
refractory septic shock, isolated veno–venous (VV) or
veno–arterial (VA) extracorporeal membrane oxygenation
(ECMO) may lead to differential hypoxia or inadequate
tissue perfusion [1]. In this context, MacLaren et al. [2]
showed that central ECMO improved the outcomes by
guaranteeing systemic oxygenation without differential
hypoxia. However, central ECMO has potential limitations
due to its invasiveness and the lack of evidence in adult
populations. Veno–veno–arterial (VVA) ECMO may offer
effective oxygenation and hemodynamic support without
differential hypoxia by regulating the return of oxygenated
blood to the underperfused coronary and cerebral
circulation [3–5]. Therefore, VVA mode can be an
alternative treatment modality for ARDS patients with
severe septic shock.
From October 2013 to March 2015, eight patients
experienced septic shock with ARDS (seven men and
one woman; average age 50.9 ± 5.9 years, range 18–71
years; five pneumonia-associated sepsis and three extra-
pulmonary sepsis). The baseline patient characteristics
are summarized in Additional file 1.
Before ECMO, the median mean arterial pressure
(MAP) was 40 mmHg (interquartile range (IQR) 33–46),
the median arterial lactate level was 7.8 mmol/L (IQR
6.3–16.3), and the median left ventricular ejection
fraction was 42.5 % (IQR 23.5–50.0). Despite adequate
fluid and vasopressor therapy, refractory shock proceeded.
The median amount of fluid received was 4.7 l (IQR
4.3–4.9) and the median central venous oxygen saturation* Correspondence: yumccs@nate.com
2Department of Thoracic and Cardiovascular Surgery, Pusan National
University Yangsan Hospital, the Research Institute for Convergence of
Biomedical Science and Technology, Pusan National University Yangsan
Hospital, Geumo-ro 20, Beomeo-ri, Mulgeum-eup, Yangsan-si,
Gyeongsangnam-do 626-770, Republic of Korea
Full list of author information is available at the end of the article
© 2016 Yeo et al. Open Access This article is
International License (http://creativecommons
reproduction in any medium, provided you g
the Creative Commons license, and indicate if
(http://creativecommons.org/publicdomain/zewas 81.2 % (IQR 76.9–87.5). The median dose of norepin-
ephrine was 0.7 μg/kg/min (IQR 0.6–0.8; also, vasopressin
was used in all patients and six of the eight patients were
also treated with epinephrine). All of the patients met the
criteria for severe ARDS with a median PaO2/FiO2 of 57
(IQR 51.3–76.2; Table 1). The Institutional Review Board
of Pusan National University Yangsan Hospital approved
this study and waived the need for informed consent.
After VVA ECMO support, MAP increased, while the
vasopressor dose and lactate level decreased and ad-
equate oxygenation was sustained (Table 2). The median
duration of vasopressor therapy was 24 h (IQR 18–72)
and the median duration of VVA ECMO was 3.0 days
(IQR 2.0–4.5). After 3 days, all patients had fully recov-
ered from the refractory shock and they did not develop
differential hypoxia. In addition, all patients were suc-
cessfully weaned from arterial support and vasopressor.
The overall survival rate was 50.0 %, and the successful
weaning rate was 62.5 %. The number of patients is not
enough to evaluate the feasibility, but VVA ECMO
might be an alternative bridging strategy to assist the
heart and lungs in patients with combined cardiopul-
monary failure.distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Hemodynamics and arterial blood gas parameters before ECMO
Patient Sex/Age EF (%) MAP (mmHg) P/F ratio (mmHg) PaCO2 (mmHg) pH Lactate
(mmol/L)
Norepinephrinea Vasopressina Fluid (L) ScvO2 (%)
1 F/18 18 47 83.0 30 7.19 8.5 0.8 0.04 4.7 80.0
2 M/54 50 43 52.0 29 7.18 6.2 1.0 0.04 4.6 82.3
3 M/51 10 28 58.0 34 7.26 7.1 0.7 0.04 4.2 75.0
4 M/36 50 49 71.5 30 7.17 13.5 0.5 0.04 5.0 86.0
5 M/64 40 33 77.8 83 6.90 17.2 0.7 0.04 5.3 79.5
6 M/71 40 33 56.0 45 7.10 6.5 0.7 0.04 4.5 92.0
7 M/53 45 42 51.0 36 7.17 18.0 0.7 0.04 4.7 88.0
8 M/60 50 38 41.0 43 7.28 3.0 0.5 0.04 3.8 76.0
ECMO extracorporeal membrane oxygenation, MAP mean arterial pressure syndrome, P/F ratio PaO2/FiO2 ratio, ScvO2 central venous oxygen saturation (%)
aThe dose is in μcg/kg/min
Table 2 Hemodynamic changes during VVA ECMO support
Baseline 6 h 12 h 24 h 72 h
LVEF (%) 42.5 [23.5–50.0] 50.0 [40.0–50.0] 50.0 [40.0–55.0]
MAP (mmHg) 40.0 76.0 74.0 85.5 83.0
[33.0–46.0] [62.8–101.3] [71.0–101.0] [75.3–88.3] [67.3–94.3]
Norepinephrinea 0.7 [0.6–0.8] 0.5 [0.2–0.6] 0.3 [0–0.6] 0.1 [0–0.1] 0 [0–0]
Epinephrinea 0.1 [0.0–0.2] 0 [0–0.1] 0 [0–0] 0 [0–0] 0 [0–0]
Arterial gas profile
PaO2/FiO2 57.0 102.3 133.0 147.0 162.5
[51.3–76.2] [80.3–190.0] [102.0–413.0] [111.8–184.0] [137.3–227.5]
Lactate (mmol/L) 7.8 [6.3–16.3] 5.5 [2.5–14.8] 6.3 [2.0–15.5] 7.0 [3.0–14.0] 5.0 [2.0–5.0]
pH 7.2 [7.1–7.2] 7.4 [7.3–7.5] 7.4 [7.3–7.4] 7.4 [7.4–7.5] 7.5 [7.4–7.5]
The data are presented as median [interquartile range]
VVA veno-venoarterial, ECMO extracorporeal membrane oxygenation, LVEF left ventricle ejection fraction, MAP mean arterial pressure
aThe dose is in μcg/kg/min
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